Sales & Marketing Regulators vs weight loss ads: Time to rethink the rules? “Medicated weight loss isn’t cheating.” Since I first wrote about the rise of
News Lilly uses Oscars ad to warn about 'untested' GLP-1s Eli Lilly has used an Oscars ad to urge people not to use unapproved and untested weight-loss medicines in a swipe at the compounding sector.
Patients A new GLP-1 opportunity for pharma: Supporting patients’ emo... People with obesity in Western cultures have largely been subject to shame, blame, stigma, and discrimination that condemns them for their current situation while simultaneously scorning th
R&D Weight loss gold rush: Developers vie for next blockbuster t... Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.
Market Access Weight loss treatments bring in billions but capacity remain... The high demand for weight loss treatments has made their rollout a staggered process.
R&D The race for obesity drug assets heats up The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
